Contributions
Abstract: 76
Type: Oral
Chronic diseases - such as multiple sclerosis, heart disease, cancer, and diabetes - are placing a growing burden on health care systems. In response, health care interventions are instituted as chronic disease management (CDM) programs to comprehensively managing the health of patients with chronic conditions. Frequently, health care intervention technology is implemented to facilitate their chronic disease management programs because it requires daily oversight and treatment adjustment. In patients with chronic disease, many health care professionals are involved during treatment and follow-up. This leads to information fragmentation that in turn may lead to suboptimal care. The use of this technology seems promising and is increasingly used to support information exchange. It can improve accessibility of intervention and can support health care processes whose quality and efficacy could be improved. For example, a wide range of telerehabilitation is used in patients with multiple sclerosis, however, the quality of evidence on these interventions was low. More robust trials are needed to build evidence about these interventions. Studies on phone- or internet-based interventions propose a positive effect on typical MS symptoms as fatigue or depression. We have integrated the platform MSDS 3D which can be used for clinincal documentation and management of MS patients as well as a tool to perform health care intervention using the patient portal of this software tool. Only integrated approaches will be implemented in clinical practice. Using such interventions do not need access to face-to-face therapy-based interventions, create an opportunity to develop a mobile technology platform for delivering therapy-based intervention to improve the severity and impact of symptoms in MS patients.
Disclosure: TZ has received speaking honoraria and travel expenses for scientific meetings and has been a steering committee member of clinical trials or participated in advisory boards of clinical trials with Almirall, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis and Teva Pharmaceuticals.
Abstract: 76
Type: Oral
Chronic diseases - such as multiple sclerosis, heart disease, cancer, and diabetes - are placing a growing burden on health care systems. In response, health care interventions are instituted as chronic disease management (CDM) programs to comprehensively managing the health of patients with chronic conditions. Frequently, health care intervention technology is implemented to facilitate their chronic disease management programs because it requires daily oversight and treatment adjustment. In patients with chronic disease, many health care professionals are involved during treatment and follow-up. This leads to information fragmentation that in turn may lead to suboptimal care. The use of this technology seems promising and is increasingly used to support information exchange. It can improve accessibility of intervention and can support health care processes whose quality and efficacy could be improved. For example, a wide range of telerehabilitation is used in patients with multiple sclerosis, however, the quality of evidence on these interventions was low. More robust trials are needed to build evidence about these interventions. Studies on phone- or internet-based interventions propose a positive effect on typical MS symptoms as fatigue or depression. We have integrated the platform MSDS 3D which can be used for clinincal documentation and management of MS patients as well as a tool to perform health care intervention using the patient portal of this software tool. Only integrated approaches will be implemented in clinical practice. Using such interventions do not need access to face-to-face therapy-based interventions, create an opportunity to develop a mobile technology platform for delivering therapy-based intervention to improve the severity and impact of symptoms in MS patients.
Disclosure: TZ has received speaking honoraria and travel expenses for scientific meetings and has been a steering committee member of clinical trials or participated in advisory boards of clinical trials with Almirall, Bayer Schering Pharma, Biogen Idec, EMD Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis and Teva Pharmaceuticals.